CY1114928T1 - Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης - Google Patents

Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης

Info

Publication number
CY1114928T1
CY1114928T1 CY20131100881T CY131100881T CY1114928T1 CY 1114928 T1 CY1114928 T1 CY 1114928T1 CY 20131100881 T CY20131100881 T CY 20131100881T CY 131100881 T CY131100881 T CY 131100881T CY 1114928 T1 CY1114928 T1 CY 1114928T1
Authority
CY
Cyprus
Prior art keywords
immunization
adenosine receptors
myocardial blood
myocardial
adenosine
Prior art date
Application number
CY20131100881T
Other languages
Greek (el)
English (en)
Inventor
Luiz Belardinelli
Mitchell Rosner
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1114928T1 publication Critical patent/CY1114928T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20131100881T 2004-01-27 2013-10-09 Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης CY1114928T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2004/002304 WO2005082379A1 (fr) 2004-01-27 2004-01-27 Imagerie de perfusion du myocarde utilisant des agonistes du recepteur d'adenosine
EP10011221.8A EP2366396B1 (fr) 2004-01-27 2004-01-27 Imagerie de perfusion du myocarde utilisant des agonistes de récepteur d'adénosine

Publications (1)

Publication Number Publication Date
CY1114928T1 true CY1114928T1 (el) 2016-12-14

Family

ID=34912870

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100881T CY1114928T1 (el) 2004-01-27 2013-10-09 Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης
CY20131100913T CY1115926T1 (el) 2004-01-27 2013-10-16 Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20131100913T CY1115926T1 (el) 2004-01-27 2013-10-16 Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης

Country Status (16)

Country Link
EP (2) EP2366396B1 (fr)
JP (1) JP4818127B2 (fr)
KR (1) KR101143826B1 (fr)
CN (1) CN1905887A (fr)
AU (1) AU2004316372B2 (fr)
CA (2) CA2691611A1 (fr)
CY (2) CY1114928T1 (fr)
DK (2) DK1708721T3 (fr)
ES (2) ES2426913T3 (fr)
HK (1) HK1162139A1 (fr)
IL (1) IL177119A (fr)
NO (1) NO337132B1 (fr)
NZ (1) NZ548794A (fr)
PT (2) PT1708721E (fr)
SI (2) SI1708721T1 (fr)
WO (1) WO2005082379A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
CA2671940A1 (fr) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a2a
JP2005538190A (ja) 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
CA2583185A1 (fr) * 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Utilisation d'agonistes du recepteur de l'adenosine a2a
KR101494125B1 (ko) 2006-02-03 2015-02-16 길리애드 사이언시즈, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
WO2008086096A2 (fr) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Imagerie de perfusion myocardique
US20110044904A1 (en) * 2008-02-29 2011-02-24 Moorman Allan R Crystal forms of 2--adenosine
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
RU2502461C1 (ru) * 2012-06-04 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РКНПК" Минздравсоцразвития России) Способ диагностики ишемии миокарда у больных кардиальным синдромом х
EP3506947A4 (fr) * 2016-09-01 2020-06-03 Leiutis Pharmaceuticals Pvt. Ltd. Formulations pharmaceutiques de régadénosone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
CA2671940A1 (fr) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a2a
JP2005538190A (ja) * 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング

Also Published As

Publication number Publication date
NZ548794A (en) 2009-07-31
KR20060130630A (ko) 2006-12-19
EP1708721B1 (fr) 2013-08-07
AU2004316372A1 (en) 2005-09-09
EP1708721A1 (fr) 2006-10-11
DK1708721T3 (da) 2013-09-08
CA2554169C (fr) 2010-03-16
ES2426913T8 (es) 2013-12-16
EP2366396A1 (fr) 2011-09-21
CY1115926T1 (el) 2017-01-25
AU2004316372B2 (en) 2011-05-12
PT2366396E (pt) 2013-10-03
CA2691611A1 (fr) 2005-09-09
ES2426913T3 (es) 2013-10-25
SI2366396T1 (sl) 2013-10-30
JP2007519718A (ja) 2007-07-19
PT1708721E (pt) 2013-10-02
WO2005082379A1 (fr) 2005-09-09
HK1162139A1 (en) 2012-08-24
NO20063629L (no) 2006-10-26
KR101143826B1 (ko) 2012-05-11
CN1905887A (zh) 2007-01-31
EP2366396B1 (fr) 2013-08-07
DK2366396T3 (da) 2013-09-08
ES2428843T8 (es) 2013-12-26
IL177119A0 (en) 2008-03-20
ES2428843T3 (es) 2013-11-11
IL177119A (en) 2011-07-31
SI1708721T1 (sl) 2013-10-30
CA2554169A1 (fr) 2005-09-09
NO337132B1 (no) 2016-01-25
JP4818127B2 (ja) 2011-11-16
WO2005082379A8 (fr) 2006-01-19

Similar Documents

Publication Publication Date Title
CY1114928T1 (el) Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
CY1113159T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
EA200701705A1 (ru) Антагонисты рецепторы глюкагона, получение и терапевтическое применение
CY1117286T1 (el) Μεσα και μεθοδοι για την αντιμετωπιση μυϊκων διαταραχων
EA201000211A1 (ru) Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
CY1109787T1 (el) Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CL2004000860A1 (es) Compuesto biciclico de pirazol o imidazol de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de un medicam
ECSP10010322A (es) Anticuerpos contra el virus de la influenza y métodos de uso de los mismos
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CY1108421T1 (el) Η χρηση σκευασματων μελοξικαμης στην κτηνιατρικη
BRPI0314038B8 (pt) anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
ATE540673T1 (de) Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
PA8659301A1 (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1
NO20072540L (no) Anvendelse av A2A-adenosinreseptoragonist
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
Zhou et al. Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors
PE20061195A1 (es) Derivado de bencimidazol como antagonista de angiotensina ii